Read ASMS_08_Angela-web.pdf text version

Method Development of LC-MS/MS Analysis of Aminoglycoside Drugs: Challenges and Solutions

Angela (Qi) Shen, Ling Morgan, Marcele L. Barroso, and Xin Zhang; Tandem Labs Tuyen Nguyen; Sepracor Inc.


The aminoglycosides are mainstream drugs used in the treatment of serious gram-negative systemic infections. They irreversibly bind to the ribosome site and other cellular structures in order to interrupt the protein synthesis. The common feature of these drugs is an aminocyditol ring linked to an amino sugar in the structure. Therefore, these drugs are highly soluble in water, exhibit low plasma protein binding, and are more than 90% excreted through the kidney. Herein, we share our experiences with LC-MS/MS method development for the analysis of aminoglycosides in plasma samples with HILIC and ion pairing chromatography.

DAtA ACquiSition

API4000 or API5000, utilizing ESI mode, were needed for required

"Acid" TreATmeNT

Simple protein precipitation was used with a ratio of 1:6, Sample: Acetonitrile. (Cold internal standard in Acetonitrile solution is preferred to generate cleaner sample extract for LC-MS/MS analysis.) Acidification of samples prior to PPT proved to be the key step for good recovery.

HiLiC ConDition:

Mobile phases:

ion pAirinG CHroMAtoGrApHy

Mobile phases:


We report two different LC-MS/MS approaches for the analysis of aminoglycosides using ion pairing and HILIC. Care must be taken during the sample preparation step, since severe non-specific binding to glass and some binding to plastic were observed. Pre-treating the sample with acid is critical for good compound recovery from the samples. Both ion pairing and HILIC demonstrate good chromatography for majority of compounds tested. We also observed that ion pairing chromatography demonstrated better detection limits for three of the compounds. Both ion pairing and HILIC have comparable detection limits for Spectinomycin. Further optimization of HILIC conditions to improve sensitivity is needed for all compounds.

LLOQs for each analyte under different experimental conditions. Analyst 1.4.2 was used for regression and linearity calculations.

Figure 1. Model Compound Chemical Structures

1. MPA: 5 or 25 mM Ammonium Formate in Milli-Q water with Formic Acid (pH = ~2.5) 2. MPB: Acetonitrile with 1% (v:v) Formic Acid

HpLC Column: SeQuant Zic-HILIC 50 X 2.0 mm, 5 µm particle size.

1. MPA: 10 mM Nonafluoropentanoic Acid with 10 mM Ammonium Hydroxide in Milli-Q water. 2. MPB: 5 mM Nonafluoropentanoic Acid with 5 mM Ammonium Hydroxide in 10:90 mixture of Milli-Q water:Acetonitrile

HpLC Column: Agilent Zorbax SB-C8 30 X 2.0 mm, 5 µm particle size.

Figure 2. Initial Result of Treatment of Plasma Sample with Acid

Flow rate: 600 µL/min

Flow rate: 500 µL/min Gradient profile: Hold initial 90% of MPB for 0.5 minutes; decrease to


To develop a reliable and generic LC-MS/MS method to quantify the aminoglycoside class of drugs.

10% of MPB at 1.0 minute; retain at 10% of MPB for 3 minutes; return to 90% of MPB for column conditioning.

Gradient profile: Hold initial 20% of MPB for 0.5 minutes; increase to

90% of MPB for 2.4 minutes; retain 90% of MPB for 0.5 minutes; return to 20% of MPB for column conditioning.

Figure 4. HILIC: Impact of Different Concentrations of Ammonium Formate: 20 mM vs 5 mM (ion suppression)

Figure 5. Ion Pairing Chromatography


SAMpLe GenerAtion

1. Sample Matrix: Mouse, Rat and Guinea Pig Plasma with K2EDTA as the anti-coagulant. (Spiking solution approach was employed in the preparation of all standard and QC calibrants.) 2. Sample treatment: Acid treated plasma samples underwent protein precipitation with a ratio of 1:6, Sample:Acetonitrile. (Cold internal standard prepared in Acetonitrile was preferred to generate cleaner sample extract for LC-MS/MS analysis.) The transferred supernatant was dried down and reconstituted with 1% Formic Acid (FA) in water, or initial MPA/MPB composition of LC conditions. 3. internal Standard: Vancomycin and glyburide.

resuLts and discussion

SAMpLe prepArAtion

NoNspecific BiNdiNg:

Initially, an inconsistent LLOQ was obtained during amikacin analysis.

optimization: After a series of experiments, 10% v:v of 3N HCl was determined to be a suitable choice for minimum sample volume of 25µL. After PPT, the sample supernatant was transferred and dried down. Initial LC composition of MPA/MPB was determined the preferred choice for the re-con solution.

Investigational experiments were conducted and revealed non-specific binding for all four compounds.

Figure 3. Selective Ion Pairing Chromatograms: "untreated" versus acid "treated"

Table 1. A brief summary of the situations tested

The major advantage of the employment of ion pairing chromatography is the improvement of the detection limit for all analytes by 10 fold (see Table 2). In addition, ion suppression phenomenon is manageable (data is not shown here). We did observe column related carry-over issues. The detail is summarized in Table 3 below.

LC ConDitionS

Two types of LC conditions were employed for the analysis: ion pairing

Table 3. Summary of Carryover Evaluation

1. All four compounds exhibit severe binding to glass vials after four consecutive transfer steps among four regular 4mL glass vials. 2. All four compounds bind to plastic tubes. Gentamicin and amikacin are more severe than the other two. 3. Addition of organic acid, such as 1% FA in stock solution eases the non specific binding to glass vials, as well as plastic tubes and 96 well plates.

chromatography and HILIC. (See details in each respective section.)

MS ConDitionS

MRM mode and electrospray ionization mode (ESI), in positive, were employed for all analytes.

Amikacin: 586.7 > 163.2; Streptomycin: 582.7 > 263.2 Spectinomycin: 333.2 > 98.0; Gentamicin: 478.6 > 160.3 Vancomycin: 724.8 > 144.2; Glyburide: 494.5 > 369.1

Decreasing the concentration of Ammonium Formate from 20 mM to 5 mM in MPA improved the MS response for all analytes due to ion suppression reduction. On the other hand, such change had negative impact on the chromatography for gentamycin analysis.

Table 2. Summary of LLOQ for Four Compounds Under Different Conditions


1 pages

Report File (DMCA)

Our content is added by our users. We aim to remove reported files within 1 working day. Please use this link to notify us:

Report this file as copyright or inappropriate


You might also be interested in

HPLC Troubleshooting Cover